Laborie Medical Technologies has taken another step in a steady cadence of acquisitions, picking up prostate balloon treatment maker Urotronic in a deal worth up to $600 million. The transaction ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--Embolx, Inc., a medical device company developing microcatheters for arterial embolization procedures, today announced that the company has received 510(k) ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--Embolx, Inc., a medical device company developing microcatheters for arterial embolization procedures, today announced CE Certifications for its next-generation ...

The FDA has expanded the use of a drug-coated balloon developed by Urotronic for male urinary procedures, which the company describes as one of the first of a new generation of devices in the space.

Aside from skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States, according to the American Urological Association. In fact, more than 288,000 new cases of ...

HOUSTON, July 31, 2018 /PRNewswire/ -- RadiaDyne, the designer and manufacturer of the market leading Endorectal Balloon device utilized during radiation therapy for prostate cancer, announced today a ...

BETHLEHEM, Pa., Nov. 7, 2025 /PRNewswire/ -- Following publication of BioProtect's pivotal randomized trial in the International Journal of Radiation Oncology, Biology, Physics (Red Journal) and ...

After skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States. In fact, one in eight men will be diagnosed with prostate cancer during their lifetime, ...